PMID- 3324494
OWN - NLM
STAT- MEDLINE
DCOM- 19880318
LR  - 20131121
IS  - 0043-5325 (Print)
IS  - 0043-5325 (Linking)
VI  - 99
IP  - 23
DP  - 1987 Dec 4
TI  - [Subacute cutaneous lupus erythematosus: clinical aspects, immunology and 
      therapy].
PG  - 802-7
AB  - Subacute cutaneous lupus erythematosus (SCLE) is a distinct subset of cutaneous 
      lupus erythematosus which is defined by clinical and immunological 
      characteristics. With regard to clinical expression and prognosis, SCLE assumes 
      an intermediate position within the spectrum of LE between purely cutaneous 
      discoid and systemic lupus erythematosus. The main clinical characteristics of 
      SCLE are extensive papulosquamous or anular lesions and photosensitivity. The 
      disease is frequently associated with Sjogren's syndrome and systemic symptoms, 
      mainly arthralgia. Renal involvement is, however, rare. Circulating Ro-antibodies 
      represent the main autoimmune phenomenon. An immunogenetic disposition to develop 
      SCLE is evidenced by the detection of the HLA-B8, DR3-phenotype in a large 
      proportion of patients. Drug therapy comprises primarily glucocorticosteroids and 
      antimalarials, but retinoids have recently also proved highly effective.
FAU - Ruzicka, T
AU  - Ruzicka T
AD  - Dermatologische Klinik und Poliklinik, Ludwig-Maximilians-Universitat Munchen, 
      Bundesrepublik Deutschland.
FAU - Bieber, T
AU  - Bieber T
FAU - Meurer, M
AU  - Meurer M
LA  - ger
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Subakuter kutaner Lupus erythematodes: Klinik, Immunologie und Therapie.
PL  - Austria
TA  - Wien Klin Wochenschr
JT  - Wiener klinische Wochenschrift
JID - 21620870R
RN  - 0 (Antibodies, Antinuclear)
RN  - 65M2UDR9AG (Etretinate)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antibodies, Antinuclear/*analysis
MH  - Cyclophosphamide/therapeutic use
MH  - DNA/*immunology
MH  - Etretinate/therapeutic use
MH  - Female
MH  - Fluorescent Antibody Technique
MH  - Humans
MH  - Lupus Erythematosus, Cutaneous/drug therapy/*immunology
MH  - Male
EDAT- 1987/12/04 00:00
MHDA- 1987/12/04 00:01
CRDT- 1987/12/04 00:00
PHST- 1987/12/04 00:00 [pubmed]
PHST- 1987/12/04 00:01 [medline]
PHST- 1987/12/04 00:00 [entrez]
PST - ppublish
SO  - Wien Klin Wochenschr. 1987 Dec 4;99(23):802-7.